Bank of America Securities analyst Geoff Meacham reiterated a Hold rating on Amylyx Pharmaceuticals Inc (AMLX – Research Report) on May 10 and set a price target of $3.50. The company’s shares opened today at $1.80.
According to TipRanks, Meacham is a 4-star analyst with an average return of 3.0% and a 49.46% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Eli Lilly & Co, and Moderna.
Currently, the analyst consensus on Amylyx Pharmaceuticals Inc is a Hold with an average price target of $4.50.
AMLX market cap is currently $119.4M and has a P/E ratio of -1.64.
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AMLX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Amylyx Pharmaceuticals Inc (AMLX) Company Description:
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases.
Read More on AMLX:
